JP2014516088A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516088A5
JP2014516088A5 JP2014514934A JP2014514934A JP2014516088A5 JP 2014516088 A5 JP2014516088 A5 JP 2014516088A5 JP 2014514934 A JP2014514934 A JP 2014514934A JP 2014514934 A JP2014514934 A JP 2014514934A JP 2014516088 A5 JP2014516088 A5 JP 2014516088A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
rvwf
vwf
subject
von willebrand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516088A (ja
JP6347468B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041957 external-priority patent/WO2012171031A1/en
Publication of JP2014516088A publication Critical patent/JP2014516088A/ja
Publication of JP2014516088A5 publication Critical patent/JP2014516088A5/ja
Application granted granted Critical
Publication of JP6347468B2 publication Critical patent/JP6347468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514934A 2011-06-10 2012-06-11 組換えフォンウィルブランド因子の投与による凝固疾患の治療 Active JP6347468B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016137381A Division JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Publications (3)

Publication Number Publication Date
JP2014516088A JP2014516088A (ja) 2014-07-07
JP2014516088A5 true JP2014516088A5 (cg-RX-API-DMAC7.html) 2015-07-30
JP6347468B2 JP6347468B2 (ja) 2018-06-27

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014514934A Active JP6347468B2 (ja) 2011-06-10 2012-06-11 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2016137381A Active JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2018246475A Pending JP2019048892A (ja) 2011-06-10 2018-12-28 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016137381A Active JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2018246475A Pending JP2019048892A (ja) 2011-06-10 2018-12-28 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Country Status (24)

Country Link
US (2) US9272021B2 (cg-RX-API-DMAC7.html)
EP (3) EP3858375B1 (cg-RX-API-DMAC7.html)
JP (3) JP6347468B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190041032A (cg-RX-API-DMAC7.html)
CN (3) CN107412743B (cg-RX-API-DMAC7.html)
AR (1) AR086904A1 (cg-RX-API-DMAC7.html)
AU (5) AU2012267458A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013031795A2 (cg-RX-API-DMAC7.html)
CA (1) CA2838845C (cg-RX-API-DMAC7.html)
DK (3) DK3412305T3 (cg-RX-API-DMAC7.html)
ES (3) ES2860450T3 (cg-RX-API-DMAC7.html)
FI (1) FI3858375T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257436A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180962T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039317T2 (cg-RX-API-DMAC7.html)
LT (1) LT2717905T (cg-RX-API-DMAC7.html)
MX (2) MX350582B (cg-RX-API-DMAC7.html)
PL (3) PL3412305T3 (cg-RX-API-DMAC7.html)
PT (3) PT2717905T (cg-RX-API-DMAC7.html)
RU (2) RU2628537C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201604684WA (cg-RX-API-DMAC7.html)
SI (1) SI2717905T1 (cg-RX-API-DMAC7.html)
TR (1) TR201808823T4 (cg-RX-API-DMAC7.html)
WO (1) WO2012171031A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086904A1 (es) * 2011-06-10 2014-01-29 Baxter Int Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf)
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
AU2018298232B2 (en) * 2017-07-07 2025-04-03 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
EA202092223A1 (ru) * 2018-03-21 2021-02-10 Баксалта Инкорпорейтед Разделение vwf и пропептида vwf хроматографическими методами
CN113645993A (zh) * 2019-02-01 2021-11-12 武田药品工业株式会社 使用重组VWF(rVWF)进行预防性治疗的方法
JP2022547556A (ja) * 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体c1qの複合体に関連する治療法
CN115335074A (zh) 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
JP2023552281A (ja) * 2020-11-24 2023-12-15 バンド セラピューティクス エルエルシー 出血障害の治療のための組成物および方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
DK2522717T3 (da) 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのvwf安定化fviii製剤及びfviiiなしのvwf製剤の使用
WO2009062100A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
AR069989A1 (es) * 2007-12-28 2010-03-03 Baxter Int Formulaciones de vwf recombinantes
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
KR101772674B1 (ko) * 2008-10-21 2017-09-01 박스알타 인코퍼레이티드 동결건조된 재조합 vwf 제제
EP2462231A2 (en) * 2009-08-04 2012-06-13 Baxter International Inc Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
SG10201809632XA (en) 2010-07-08 2018-12-28 Baxalta Inc METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
AR086904A1 (es) * 2011-06-10 2014-01-29 Baxter Int Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf)

Similar Documents

Publication Publication Date Title
JP2014516088A5 (cg-RX-API-DMAC7.html)
RU2017102679A (ru) Лечение нарушений свертываемости крови путем введения рекомбинантного фв
CN103917554B (zh) 用于改善重构后纯化的因子viii的稳定性的方法
Lethagen et al. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III
Federici et al. Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study
JP2011527301A5 (cg-RX-API-DMAC7.html)
JP2014530873A5 (cg-RX-API-DMAC7.html)
NZ701205A (en) Optimised subcutaneous therapeutic agents
EP4255566A1 (en) Treatment of hemophilia with fitusiran
ES2595160T3 (es) Uso combinado de un glucosaminoglicano sulfatado y una hialuronidasa para mejorar la biodisponibilidad del Factor VIII
JP2014504601A5 (cg-RX-API-DMAC7.html)
FI3648788T3 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
MX2009013183A (es) Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso.
JP2014530246A5 (cg-RX-API-DMAC7.html)
KR20140083036A (ko) 인자 viii의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
TW202021611A (zh) 用於治療再生不良性貧血之醫藥組合物
Ciccozzi et al. cAsɛ sruov
JP2015524808A5 (cg-RX-API-DMAC7.html)
McDaniel Treatment of Hemophilia A and B
AR118608A2 (es) TRATAMIENTO DE LOS TRASTORNOS DE LA COAGULACIÓN MEDIANTE LA ADMINISTRACIÓN DE UN FACTOR DE VON WILLEBRAND (vWF) RECOMBINANTE
AU2019202876B2 (en) Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders
JP2019524089A5 (cg-RX-API-DMAC7.html)
Nogami et al. Pathogenesis and treatment of hemophilia
EP1635861A1 (en) Compositions comprising factor viii and factor ixa for treating haemophilia
MX2024001882A (es) Metodo para producir factor viii / factor de von willebrand derivado de plasma humano y composicion obtenida.